EyePoint Pharmaceuticals Inc (FRA:PV3B)
€ 7.932 0.038 (0.48%) Market Cap: 409.05 Mil Enterprise Value: 136.42 Mil PE Ratio: 0 PB Ratio: 1.69 GF Score: 61/100

EyePoint Pharmaceuticals Inc Six-Month Transition Period Ended December 31, 2018 Earnings Call Transcript

Mar 14, 2019 / 12:30PM GMT
Release Date Price: €22.5 (-1.75%)
Operator

Good morning. My name is Amanda, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharma's Fiscal Period Ended December 31, 2018 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Mr. David Price, EyePoint's Chief Financial Officer.

David J. Price
EyePoint Pharmaceuticals, Inc. - CFO

Thank you, Amanda, and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' fiscal period ended December 31, 2018 financial results and recent corporate developments. With me today is Nancy Lurker, EyePoint's President and Chief Executive Officer.

Nancy will provide an overview of the recent progress made on our commercial and pipeline programs as well as highlight upcoming milestones. I will then provide an overview of the 3 and 6-month financial results for the fiscal period ended December 31, 2018. We will then open the call up for your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot